Replacing Refined Carbohydrates With Healthy Fats on Cardio-metabolic Markers

Metabolic Syndrome Clinical Trial

— AV2  

Official title:

Effects of a Typical American Diet High in Refined Carbohydrates Compared to a Diet That Replaces Some Refined Carbohydrates With Healthy Fats on Cardiometabolic Health in Men and Women With Pre-diabetes and Metabolic Syndrome

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02695433
• Other study ID #: IRB2016-001
• Status: Completed
• Phase: N/A
• Start date: March 1, 2016
• Est. completion date: May 15, 2021

Study information

• Verified date: June 2021
• Source: Clinical Nutrition Research Center, Illinois Institute of Technology
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary goal is to to characterize the effects of consuming 1 avocado fruit 7 days / week (5-7 days is acceptable) compared to a no avocado relatively low fat, carbohydrate control treatment over a 12 week period on insulin sensitivity as measured by the Matsuda composite index of insulin sensitivity (MISI).

Description:

The trial is designed as a randomized, controlled, statistician blinded, 2-arm parallel study to investigate the effects of avocado consumption compared to non-avocado control foods which have opposing macronutrients (avocado is relatively higher in fat and in low carbohydrate and the control foods will be low fat, high carbohydrate options) on indices of cardiometabolic health over a 12 week period.

The trial will test 2 treatment conditions in pre-diabetic men and women 25-60 years of age with metabolic syndrome. One hundred twenty men and women will be recruited, aiming for a completer set of 96 subjects. Qualified Subjects will be randomized to receive 1 of 2 test treatments based on randomization schedule from a computer generated randomization schedule.

Study treatments include:

• Control (CT) diet plan with at least 1 serving of a low fat, low fiber, high glycemic carbohydrate and eliminate avocado 7 days / week (5-7 days is acceptable) over a 12 week period.

• Active treatment (AT) diet plan will include 1 Avocado 7 days/week (5-7 days is acceptable) over a 12 week period.

Each subject will be asked to come for one Screening Visit, 9 interim food pick-up/compliance visits and 4 Test Day Visits. The four main Test Day visits will occur at week 0 (day 1; baseline), end of week 4, at the end of week 8 and at the end of week 12. Interim Visits will occur at week 1, 2, 3, 5, 6, 7, 9, 10 and 11. Subjects will pick-up study foods, answer questionnaires, receive dietary counseling, confirm diet compliance during interim visits. They will also be asked to complete online 24 hour food recalls up to once per each week of the study. Each of the 4 Test Day Visits will last about 2-3.5 h and involve blood pressure (BP) measurements, a fasting blood sample collection and anthropometric, body composition assessment. In addition, an oral glucose tolerance test (OGTT) will be performed at week 0/day 1 and at the end of week 12/day.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 124
• Est. completion date: May 15, 2021
• Est. primary completion date: January 20, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 25 Years to 60 Years

Eligibility

Inclusion Criteria:

• Men and women aged 25-65 yrs.

• BMI of 25 - 42 kg/m2

• HOMA-IR = 2

• Abdominal obesity: mid-point waist circumference >102 cm for men and >88 cm for women

• No clinical evidence / history of heart disease, respiratory, renal, gastrointestinal, or hepatic disease

• Not taking over-the-counter or prescription medications/dietary supplements that may interfere with study procedures or endpoints (e.g., antioxidant supplements, protein powder, energy drinks, anti-inflammatory or lipid-lowering medications).

• Non-smoker or past smoker (smoking cessation > 2 yrs.)

• Able to provide informed consent and comply with study procedures

Exclusion Criteria:

• Aged < 25 or > 65 years

• BMI < 25 kg/m2 or > 42 kg/m2

• HOMA-IR < 2.0

• History of heart disease, respiratory, renal, gastrointestinal or hepatic disease

• Diabetes

• Have or had cancer other than non-melanoma skin cancer in past 5 years

• Taking over-the-counter or prescription medications or dietary supplements that may interfere with study procedures or endpoints (including protein powers, energy drinks)

• Vegan dietary habits, unusual dietary habits or sensitive or allergic to any of the test meal components / ingredients

• Consuming 3 or more avocados per week.

• Consuming 3 or more servings of nuts or peanuts per week, unless subject is willing to stop consuming nuts 4 weeks before and throughout the course of the study.

• Excessive coffee and tea consumers (>4 cups/day)

• Current smoker

• Actively losing weight or trying to lose weight (unstable body weight fluctuations of > 5 kg in 3 months

• Drug or alcohol addiction

• Present with significant psychiatric or neurological disturbances

• Working overnight (e.g 3rd shift of overnight workers)

• Pregnant, lactating or planning to become pregnant

• Have donated blood within 3 months of the screening visit and blood donors/participants for whom participation in this study will result in having donated more than 1500 milliliters of blood in the previous 12 months.

• Women who are taking unstable dose and brand of hormonal contraceptive and/or stable dose and brand less than 6 months

• Excessive exercisers or trained athletes

• Take part in chronic feeding or medication clinical trial in the last 3 months

Related Conditions & MeSH terms

• Glucose Intolerance
• Metabolic Syndrome
• Pre-diabetes
• Prediabetic State
• Syndrome

Intervention

Dietary Supplement:
• Active
Active Treatment Diet Plan
• Control
Control Diet Plan

Locations

Country	Name	City	State
United States	Clinical Nutrition Research Center	Chicago	Illinois

Sponsors (1)

Lead Sponsor	Collaborator
Clinical Nutrition Research Center, Illinois Institute of Technology

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Changes in body weight in 12-week intervention of active treatment vs control treatment.	body weight in 12-week intervention	baseline and 12 weeks
Other	Changes in waist circumference in 12-week intervention of active treatment vs control treatment.	waist circumference in 12-week intervention	baseline and 12 weeks
Other	Changes in body composition in 12-week intervention of active treatment vs control treatment.	body composition in 12-week intervention	baseline and 12 weeks
Other	Changes in blood lipoproteins in 12-week intervention of active treatment vs control treatment.	Changes in lipoprotein particle size/density by nuclear magnetic resonance (NMR)	baseline and 12 weeks
Other	Changes in blood IL-6 in 12-week intervention of active treatment vs control treatment.	blood IL-6 in 12-week intervention	baseline and 12 weeks
Other	Changes in blood MCP-1 in 12-week intervention of active treatment vs control treatment.	blood MCP-1 in 12-week intervention	baseline and 12 weeks
Primary	Changes in insulin sensitivity as measured by the Matsuda composite index of insulin sensitivity (MISI) in 12-week intervention of active treatment vs control treatment.	insulin sensitivity as measured by the Matsuda composite index	baseline and 12 weeks
Secondary	Changes in fasting blood glucose response in 12-week intervention of active treatment vs control treatment.	fasting blood glucose response in 12-week intervention	baseline and 12 weeks
Secondary	Changes in fasting blood insulin response in 12-week intervention of active treatment vs control treatment.	fasting blood insulin response in 12-week intervention	baseline and 12 weeks
Secondary	Changes in fasting HbA1c response in 12-week intervention of active treatment vs control treatment.	fasting HbA1c response in 12-week intervention	baseline and 12 weeks
Secondary	Changes in blood pressure in 12-week intervention of active treatment vs control treatment.	blood pressure in 12-week intervention	baseline and 12 weeks
Secondary	Changes in fasting blood Triglycerides concentration in 12-week intervention of active treatment vs control treatment.	fasting blood Triglycerides concentration in 12-week intervention	baseline and 12 weeks
Secondary	Changes in fasting hs C-Reactive Protein in 12-week intervention of active treatment vs control treatment.	fasting hs C-Reactive Protein in 12-week intervention	baseline and 12 weeks
Secondary	Changes in fasting markers of endothelial dysfunction (ICAM-1) in 12-week intervention of active treatment vs control treatment.	fasting markers of endothelial dysfunction (ICAM-1) in 12-week intervention	baseline and 12 weeks
Secondary	Changes in fasting markers of endothelial dysfunction (VCAM-1) in 12-week intervention of active treatment vs control treatment.	fasting markers of endothelial dysfunction (VCAM-1) in 12-week intervention	baseline and 12 weeks
Secondary	Changes in attitudes towards eating measured by the Stunkard 3-Factor Eating Questionnaire in 12-week intervention of active treatment vs control treatment.	attitudes towards eating measured by the Stunkard 3-Factor Eating Questionnaire in 12-week intervention	baseline and 12 weeks
Secondary	Changes in plasma LDL cholesterol in 12-week intervention of active treatment vs control treatment.	plasma LDL cholesterol in 12-week intervention	baseline and 12 weeks
Secondary	Changes in plasma total cholesterol in 12-week intervention of active treatment vs control treatment.	plasma total cholesterol in 12-week intervention	baseline and 12 weeks
Secondary	Changes in plasma HDL cholesterol in 12-week intervention of active treatment vs control treatment.	plasma HDL cholesterol in 12-week intervention	baseline and 12 weeks